StreetInsider.com News Articles

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

Wed, 21 Oct 2026 08:30:00 -0400

MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at Neuronetics Q3 2026 Earnings. To listen to

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

Wed, 21 Oct 2026 08:30:00 -0400

B.Riley Starts Neuronetics (STIM) at Buy

Fri, 11 Sep 2026 03:04:57 -0400

B.Riley analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ: STIM) with a Buy rating and a price target of $5.00.

The analyst comments: “We are initiating coverage of Neuronetics, Inc. (STIM) with a Buy rating and $5 price target (~70% upside), following the late-2024 Greenbrook acquisition and management reset in 2026. We believe Greenbrook’s revenue growth and operating leverage may translate disproportionately into earnings, thereby supporting a revaluation of STIM from a levered TMS device company to a scaled interventional psychiatry platform. Importantly, Greenbrook provides organic mid teens growth and substantial unused capacity while also positioning STIM to benefit from a

B.Riley Starts Neuronetics (STIM) at Buy

Fri, 11 Sep 2026 03:04:57 -0400

B.Riley analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ: STIM) with a Buy rating and a price target of $5.00.

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

Tue, 08 Sep 2026 08:32:00 -0400

First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing Workflows

MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the integration of its TrakStar® practice management platform with AdvancedMD, a leading cloud-based electronic health record (EHR), practice management, and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices in the ambulatory and mental health care space. This marks a significant milestone for

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

Tue, 08 Sep 2026 08:32:00 -0400

First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing Workflows

Form SCHEDULE 13D/A Neuronetics, Inc. Filed by: Chernett Jorey

Mon, 24 Aug 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969538.html

Form SCHEDULE 13D/A Neuronetics, Inc. Filed by: Chernett Jorey

Mon, 24 Aug 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26969538.html

Form 144 Neuronetics, Inc. Filed by: MACAN WILLIAM ANDREW

Wed, 19 Aug 2026 14:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26949471.html

Form 144 Neuronetics, Inc. Filed by: MACAN WILLIAM ANDREW

Wed, 19 Aug 2026 14:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26949471.html

Form 144 Neuronetics, Inc. Filed by: MACAN WILLIAM ANDREW

Tue, 18 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260818/26945056.html

Form 144 Neuronetics, Inc. Filed by: MACAN WILLIAM ANDREW

Tue, 18 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260818/26945056.html

Form 8-K Neuronetics, Inc. For: Aug 11

Mon, 17 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26938038.html

Form 8-K Neuronetics, Inc. For: Aug 11

Mon, 17 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26938038.html

Form 4 Neuronetics, Inc. For: Aug 13 Filed by: Chernett Jorey

Mon, 17 Aug 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260817/26936216.html

Form 4 Neuronetics, Inc. For: Aug 13 Filed by: Chernett Jorey

Mon, 17 Aug 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260817/26936216.html

Form SCHEDULE 13G Neuronetics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930807.html

Form SCHEDULE 13G Neuronetics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930807.html

Form S-8 Neuronetics, Inc.

Tue, 11 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26907202.html

Form S-8 Neuronetics, Inc.

Tue, 11 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26907202.html

Form 10-Q Neuronetics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260811/26906234.html

Form 10-Q Neuronetics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260811/26906234.html

Neuronetics (STIM) PT Raised to $6 at BTIG

Tue, 11 Aug 2026 13:54:28 -0400

(Updated - August 11, 2026 1:54 PM EDT)

BTIG analyst Sam Eiber raised the price target on Neuronetics (NASDAQ: STIM) to $6.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "Neuronetics delivered a top-line Q2 beat with total revenue of $41.6M (+9% y/y; consensus $40.2M), but the most notable development was the company's first inflection into positive adjusted EBITDA territory at $0.3M (consensus -$3.7M). Results were driven by another strong quarter from the Greenbrook clinic business (+17% y/y), with continued momentum across both Spravato and TMS and improved reimbursement rates. Revenue cycle management improvements (more disciplined patient eligibility qualification upfront,

Neuronetics (STIM) PT Raised to $6 at BTIG

Tue, 11 Aug 2026 13:54:28 -0400

(Updated - August 11, 2026 1:54 PM EDT)

BTIG analyst Sam Eiber raised the price target on Neuronetics (NASDAQ: STIM) to $6.00 (from $5.00) while maintaining a Buy rating.

Form 8-K Neuronetics, Inc. For: Aug 11

Tue, 11 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260811/26901907.html